Glucotrack 8-K details Regulation FD press release

Glucotrack, Inc. filed a Form 8-K to report that it issued a press release on October 29, 2025.

Accepted by SEC EDGAR 10/29/2025 - 04:19 PM EDT

(Moderate)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Glucotrack, Inc. filed a Form 8-K to report that it issued a press release on October 29, 2025. The company furnished this press release as Exhibit 99.1 under Item 7.01, Regulation FD Disclosure. The filing does not add financial statements or describe specific transaction details.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Glucotrack (GCTK) disclose in its October 29, 2025 Form 8-K?

Glucotrack disclosed that it issued a press release on October 29, 2025 and furnished it as Exhibit 99.1 under Item 7.01, Regulation FD Disclosure. The filing itself does not provide the press release content or additional financial details.

What is the main purpose of Glucotrack’s Regulation FD 8-K for GCTK?

The main purpose is to formally furnish a company press release under Regulation FD, ensuring broad, fair disclosure to the market. The 8-K identifies the press release as Exhibit 99.1 and clarifies its treatment as “furnished,” rather than “filed,” for liability purposes.

How is the Glucotrack (GCTK) press release treated under the Exchange Act?

The press release attached as Exhibit 99.1 is treated as “furnished,” not “filed,” under Section 18 of the Exchange Act. This means it is not automatically subject to Section 18 liabilities unless Glucotrack later specifically incorporates it into another filing.

Which exhibit is included in Glucotrack’s October 29, 2025 Form 8-K?

The Form 8-K includes Exhibit 99.1, described as a press release dated October 29, 2025, and Exhibit 104, the cover page interactive data file embedded within the inline XBRL document. These exhibits support the Regulation FD disclosure structure of the current report.

Does Glucotrack’s October 29, 2025 8-K for GCTK contain new financial statements?

No. The 8-K lists Item 9.01 for financial statements and exhibits but only identifies exhibits, including the press release and cover page data file. It does not attach separate financial statements or quantify new financial performance information within the text provided.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 29, 2025

GLUCOTRACK, INC.

(Exact name of registrant as specified in its charter)

Delaware	001-41141	98-0668934
(State or Other Jurisdiction	(Commission	(IRS Employer
of Incorporation)	File Number)	Identification No.)

301 Rte. 17 North, Ste. 800, Rutherford, NJ		07070
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (201) 842-7715

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		GCTK		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure

On October 29, 2025, Glucotrack, Inc., a Delaware corporation (the “Company”), issued a press release (the “Press Release”). The Press Release is furnished herewith as Exhibit 99.1.

The information in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, unless the Company specifically states that the information is to be considered “filed” under the Exchange Act or specifically incorporates it by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No.		Description
99.1		Press Release dated October 29, 2025
104		Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 29, 2025

	GLUCOTRACK, INC.

	By:	/s/ Paul Goode
	Name:	Paul Goode
	Title:	Chief Executive Officer

Source: View Original Filing on SEC EDGAR